ADVANCING NEW THERAPEUTIC HORIZONS FOR PATIENTS

HARNESSING NOVEL PHYSIOCRINE BIOLOGY TO PROMOTE HOMEOSTASIS

CORPORATE PRESENTATION JANUARY, 2017



Forward-Looking Statements

The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," "opportunity," or "continue," and other similar expressions are intended to identify forwardlooking statements. For example, all statements we make regarding the potential therapeutic benefits of Physiocrines and our product candidates, including Resolaris[™] and Stalaris[™], the ability to successfully advance our pipeline or product candidates, the timing within which we expect to initiate, receive and report data from, and complete our planned clinical trials, and our ability to receive regulatory approvals for, and commercialize, our product candidates, our ability to identify and discover additional product candidates, our projected cash expenditures, and the ability of our intellectual property portfolio to provide protection are forward-looking statements. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. These risks, uncertainties and other factors are more fully described in our filings with the U.S. Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q, Annual Report on Form 10-K and in our other filings. The forward-looking statements in this presentation speak only as of the date of this presentation and neither we nor any other person assume responsibility for the accuracy and completeness of any forwardlooking statement. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

We own various U.S. federal trademark applications and unregistered trademarks, including our company name and Resolaris[™]. All other trademarks or trade names referred to in this presentation are the property of their respective owners. Solely for convenience, the trademarks and trade names in this presentation are referred to without the symbols [®] and [™], but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

LIFE Value Proposition



Pioneers of new therapeutic intervention points in homeostasis - **The World of Physiocrines**



Favorable safety profile and potential clinical activity from 1st **Physiocrine** program, Resolaris, in 2 rare myopathies



Advancing 2nd Physiocrine program, Stalaris, into human trials this year



Closing in on a **3rd Physiocrine**-based opportunity as a 2017 IND candidate

Pursuing partnership(s) for one or more of the above programs to accelerate clinical and preclinical pipeline

\$76M estimated cash 2016 EOY* **\$51M** market capitalization 2016 EOY



LIFE 2016 Execution

LIFE ACCOMPLISHMENTS

Resolaris (Rare Genetic Myopathies)

- ✓ Adult FSHD: Completed blinded trial, open-label trial, with two ongoing safety extensions
- ✓ Adult LGMD2B: Completed open label trial, with ongoing safety extension
- ✓ Early Onset FSHD: Interim data provided from open label trial, with ongoing safety extension

Goals for Resolaris Development:

- ✓ Not immunosuppressive
- ✓ Favorable safety and tolerability profile in multiple myopathies
- ✓ Active dose at 3.0 mg/kg
- ✓ Narrowed potential efficacy endpoints

Stalaris (Severe Lung Diseases)

- ✓ Additional preclinical model data vs. approved drugs in idiopathic pulmonary fibrosis
- Non-human primate data
- ✓ GMP manufacturing kicked off

3rd Program (Undisclosed 3rd Attractive Therapeutic Area)

- ✓ 3rd biologics program
- ✓ Lead selection process initiated

Our team executed on milestones on time and under budget




THE POWER OF PHYSIOCRINES ORCHESTRATING HOMEOSTASIS NEW CLASS OF PROTEINS FROM ALTERNATIVE SPLICING OF ANCIENT GENES

Orchestrating Homeostatic Pathways for Novel Therapies TAPPING AN ANCIENT

Discovery of potential therapeutic intervention points


Source of Power






Evidence for Homeostatic Role of a Physiocrine in Humans Disrupting the Resokine Pathway Promotes Muscle and Lung Disease

Resokine Pathway



Free Resokine Pathway in Anti-Synthetase Patients Diminished

Resokine Pathway in Humans






Agonists of the Resokine Pathway in Immune Driven Models

Balancing the immune response to tissue insults

Resokine Pathway




In vivo administration of Resokine proteins to animal models of T cell driven disease states. Cell type indicates type of cells involved but may not be limited to these cells.

Resokine: 1st Physiocrine Pathway Harnessed

"<u>Reso</u>lution of immune <u>activity</u>"

Resokine Pathway



*HARS or histidine aminoacyl tRNA synthetase is a single gene responsible for a series of Physiocrine proteins

🚺 aTyr Pharma




RESOLARIS HARNESSING THE RESOKINE PATHWAY TO TREAT MULTIPLE RARE MUSCLE DISEASES

Rare Myopathies with an Immune Component (RMIC)

Chronic damage, homeostasis disrupted

PATHOPHYSIOLOGY

SHARED




Frisullo et al., J. Clin. Immunol., 2011. Gallardo et al. Neurology, 2001. Flanigan et al. Human Gene Therapy, 2013. **FSHD** = Facioscapulohumeral Muscular Dystrophy (FSHD). **LGMD2B** = Limb Girdle Muscular Dystrophy 2B. **DMD** = Duchenne Muscular Dystrophy.



Resolaris Tempers Activated T cells

Demonstrated effect as an immuno-modulator



On the Left: Gated on CD4⁺ T cells. Resolaris at 100 pM. 24 hours stimulation with anti-CD3/CD28 Abs. **On the Right:** T cells were stimulated with anti-CD3/CD28 antibodies in the presence of vehicle or Resolaris . After 24 h, supernatants were collected and analyzed by ELISA, Statistics by T test



First Physiocrine For Patients: Resolaris



Derived from a naturally occurring protein, the histidine aminoacyl tRNA synthetase (HARS)

- Skeletal muscle secretes Resokine
- Resokine, an agonist, plays a role in homeostasis & T cell responses in muscle
- Recombinant version of Resokine
- Demonstrated favorable safety profile and potential clinical activity in two rare myopathy indications
- Therapeutic potential for rare myopathies with an immune component (RMIC), over 20 potential indications
- Strategy: Establish broad utility across multiple indications




Few Treatment Options: FSHD, LGMD2B, & DMD

Patients Unmet Need

	<u>FSHD</u>	LGMD2B	DMD
Genetics	Toxic gain of function (DUX4 region)	Loss of function mutations (Dysferlin gene)	Loss of function mutations (Dystrophin gene)
Immune Pathology	Immune infiltration ¹ by activated T cells (CD8 ⁺)	Immune infiltrates ² of CD4 ⁺ , CD8 ⁺ and macrophages	Immune infiltrates ³ of CD4 ⁺ , CD8 ⁺
Clinical	Debilitating, progressive skeletal muscle weakness		Similar clinical symptoms to FSHD and LGMD2B, with potential severe cardiac weakness and effects, and higher morbidity
	Pain, fatigue, difficulty moving limbs, may have respiratory distress		
Standard of Care	No therapeutic treatments, only supportive care provided		Steroids and recently approved exon specific drugs
Disease Progression	Heterogeneous by muscle	Homogeneous by muscle group	Homogeneous, steeper slope, by muscle groups

¹Frisullo et al. J Clin Immunol (2011) 31:155–166
²Gallardo et al. Neurology 2001;57:2136–2138; Yin et al. Int J Clin Exp Pathol 2015;8(3):3069-3075
³Flanigan et al. Human Gene Therapy, 2013. Yin et al. Int J Clin Exp Pathol 2015.

👌 aTyr Pharma



Manual muscle strength assessed bilaterally by the modified Medical Research Council Scales (MRC) CIDD (Clinical Investigation of Duchenne Dystrophy) score, graded from 0 (worst) to 10 (best)

Percentage of Patients with Muscle

Objectives

Evaluate Safety and Tolerability

- Build safety dossier for Resolaris \checkmark
- Multiple indications, different dosing regimens, longer duration

Evaluate Potential Activity Assessments*

- Functional / Strength: MMT \checkmark
- Patient Reported Outcomes: INQoL \checkmark
- MRI / Biomarkers assessments ±

Trial	Indication(s)	Patients	Highest Dose	Design
002	Adult FSHD	3 dose cohorts (n=20 Total)	3.0 mg/kg Weekly (12 weeks)	Placebo controlled, Double blinded; Interpatient Dose Escalation up to 12 weeks
003	Early onset FSHD	Stage 1 (n=8)	3.0 mg/kg Weekly (6 weeks)	Open-label, Intrapatient Dose Escalation for 12 weeks
004	Adult LGMD2B, Adult FSHD	LGMD2B (n=10) FSHD (n=8)	3.0 mg/kg Biweekly (4 weeks)	Open-label, Intrapatient Dose Escalation for 12 weeks

*MMT = Manual Muscle Testing, a validated assessment tool that measures muscle function/strength

17 INQoL = Individualized Neuromuscular Quality of Life, a patient reported outcome measure designed specifically for neuromuscular disease




MMT Scores LGMD2B Patients (004 Trial)

Individual Patient Changes from Baseline (%)

Resolaris Program


Week 14 MMT* LGMD2B (n=9†)



*1-week follow-up is earlier than week 14 for 2 early discontinuations

⁺ One patient in 004 Trial did not have an MMT measurement due to being wheelchair bound at baseline





*Early onset FSHD (003) Trial represents interim data results (4 patients of a total of 8)



Robust Safety & Tolerability Dossier

44 patients have received Resolaris for a total drug exposure of 149 patient months

No observed immuno-suppressive effects: consistent with a homeostatic pathway

Resolaris demonstrated a favorable safety profile and was generally well-tolerated across all doses tested in multiple myopathies, various age-groups, and with long-term exposure

No Serious or Severe adverse events were reported by study investigators

No clinical symptoms observed with low-level anti-drug antibody assay signals and protocol discontinuations were primarily driven by transient infusion related reactions

Going Forward: Target Product Profile (Discontinuation Rate ≤ 10%)


- Potential to pre-medicate patients
- *Potentially relax cut-off criteria for discontinuations*

FDA lifted partial clinical hold for dosing above 3.0 mg/kg



Resolaris: One Product, Multiple RMICs

Promise for severely afflicted myopathy patients



FSHD: Average prevalence rates of FSHD are approximately 1/17,000. Applying this rate to the US population based on recent census data equals approximately 19,000. LGMD: 16,000 cases estimated in US population. 1/20,000 Wickland and Kissel, Neural. Clin. 20`14. Relative Prevalence of Limb Girdle Muscular Dystrophies in the United States Population. Wicklund et al., Neurology 2013. DMD: Prevalence of approximately 5/100,000. Orphanet Report Series - Prevalence of rare diseases: Bibliographic data - May 2014 - Number 1

21 🚺 aTyr Pharma

Resolaris Status and 2017 Development Goals

Clinical Status

- ✓ Established a favorable safety profile and identified an active dose
- ✓ Signals of clinical activity across (1) LGMD2B (2) FSHD and (3) Early onset FSHD
- ✓ Commercial scale manufacturing poised for future trials

2017 Development Goals

First Half

Clinical Results: Early Onset FSHD Patients (003)


Regulatory: Advance interactions with regulatory agencies

Biomarker/MOA: Introduce Mechanistic/PD Assay

Second Half

Clinical Trial: Kick off next trial post partnership*





STALARIS LUNG PHYSIOCRINE ENGINEERED TO TREAT MULTIPLE PULMONARY DISEASES

Interstitial Lung Disease Opportunity

Driven by a combination of immunological and fibrotic pathways

Patients Unmet Need


Interstitial Lung Disease (ILD)	Over 100 different specific disease types		
Standard of Care	Steroids and immuno-suppressants Approved therapies for IPF*: Pirfenidone & Nintedanib		
Pathology	Fibrosis Immune Component		
Pattern of Disease	NSIP Image: Signature Image: Signature <t< th=""></t<>		
Prognosis	Poor prognosis for these patients e.g. 2-3 year median survival for IPF		

Adapted from: Thannickal VJ, et al. Ann Rev Med. 2004;55:395-417 (and) 2013 ATS Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias *IPF = Idiopathic Pulmonary Fibrosis

24 🚺 aTyr Pharma

Stalaris Program: Opportunity for Lung Patients

Leverages Knowledge of Resokine Pathway in Lung




- iMod domain: Resokine splice variant relatively more expressed in *lung* than other tissues
- Fc Domain: increased exposure to potentially enable once-monthly dosing in humans
- Engineered result: Stalaris ~350x increased exposure vs. iMod; while retaining T cell modulation activity
- **1**st **molecule** from internal Fc platform

Potential Therapeutic Applications:

Rare pulmonary diseases with an immune component (RPICs) Broader reach into RPICs and interstitial lung disease (ILD) indications



iMod Domain in Lung Splice Variant Express Data for iMod in Lung




Splice variant for the iMod domain is relatively more expressed in lung than other tissues



Stalaris Tempers Activated T Cells at High Affinity


Stalaris Program



- Stalaris inhibits Th2 type cytokines from activated T cells
- Th2 cytokines play a role in promoting **fibrosis** in certain interstitial lung diseases




Knockout of Resokine Pathway Increases T Cell InvasionPost Disease InductionSTALARISRodent functional knockout inducing idiopathic pulmonary disease using BleomycinPROGRAM





Stalaris Outperforms Current Treatments

Established Rodent Model for Idiopathic Pulmonary Fibrosis (IPF)



*The Ashcroft scale for the evaluation of bleomycin-induced lung fibrosis is the analysis of stained histological samples by visual assessment

🚺 aTyr Pharma

Stalaris: Status and 2017 Development Goals

Stalaris Program

Preclinical Status:

- ✓ Activity in industry proven model of IPF (approved drugs Pirfenidone & Nintedanib)
- ✓ GMP manufacturing kicked off
- ✓ Rat/non-human primate non-GLP safety & PK data support advancement to IND

2017 Development Goals:

First Half

Biomarker/MOA: Introduce mechanistic/PD assay

IND Enabling: Initiate preclinical safety studies

Second Half

GMP Manufacturing: Complete clinical trial supply

Clinical Trial: Initiate First in human clinical trial



BUILDING A NEW CLASS OF THERAPEUTICS FOR PATIENTS FOUNDATION FOR THE FUTURE

LIFE Leaders


FOUNDATION FOR THE FUTURE





LIFE Numbers

FOUNDATION FOR THE FUTURE





2017 Goals

- Partner One or More Programs
- Advance Pipeline with Two Molecules in the Clinic
- > Declare 3rd IND Candidate from Physiocrine Discovery Engine

Financial Guidance

- \$76M estimated cash 2016 EOY*
- Operations funded into 3Q 2018 without any partnerships
- ~30% expected reduction in operational cash burn compared to 2016**
- *Estimated cash, cash equivalents, and investments provided pending completion of year-end financial close and external audit **Operational cash burn only, excludes cash from financings



THANK YOU!